ferric citrate · Keryx Biopharms · NDA 205874
Auryxia
Earliest generic entry, as listed
21 Jul 2030
Blocked by patent: US 10300039, US 9387191.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10300039 | use U-2549 | 21 Jul 2030 |
| US 9387191 | product | 21 Jul 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026First generic approved · 205874-00111 Mar 2026
- 25 Oct 2026Generic approved · 205874-00111 Mar 2026
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 205874 · 001 · RLD | tablet, oral | EQ 210MG IRON | 21 Jul 2030 |
Expired or delisted (1)
- US 8093423 · use U-1577 · 21 Apr 2026